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Objective: The aim of this study was to investigate the epidemiology and antibiotic   susceptibility 
profiles of isolated bacterial organisms in relation to empiric treatment of neutropenic fever 
over a 15-year period.
Methods: All patients with or at risk for febrile neutropenia and treated in the hematology 
ward of the Antwerp University Hospital during 1994–2008 were prospectively included. Skin, 
blood, and urine cultures were taken. Oral quinolone prophylaxis was started in patients with 
neutropenia without fever. Empiric starting therapy consisted of amikacin in combination with 
cefepime.
Results: A total of 3624 bacteria were isolated. The most common pathogens were coagulase-
negative Staphylococci (46%), followed by Escherichia coli (25%), Enterobacteriaceae (15.6%), 
Staphylococcus aureus (7.2%), and Pseudomonas aeruginosa (3.8%). The balance between 
Gram-positive and Gram-negative bacteria remained stable, with a majority of Gram-positive 
bacteria. A shift from oxacillin-sensitive to oxacillin-resistant coagulase-negative Staphylococci 
was observed. Regarding susceptibility patterns, no vancomycin resistance was detected in 
coagulase-negative Staphylococci or in S. aureus. The E. coli susceptibility rates remained stable. 
However, 66% of bloodstream infections were ciprofloxacin-resistant. A reduced susceptibility 
of P . aeruginosa strains to meropenem was noticed.
Conclusions: Improvement in antibiotic susceptibility of inducible Enterobacteriaceae 
  following a switch of empiric antibiotic therapy was maintained 15 years after starting the   latter 
treatment. Further improvement in antibiotic susceptibility of these bacteria to ceftazidime was 
observed, but continuous vigilance is warranted.
Keywords: bacterial susceptibility, febrile neutropenia, antibiotic change
Introduction
Patients with malignancy are very susceptible to nosocomial infections. Because of 
this susceptibility, impaired immune response, and the potential for infection with 
antimicrobial-resistant pathogens, patients suspected of having developed these 
  infections are commonly treated with broad-spectrum antibiotics.1 In this specific 
group of patients, the most important determinant of successful treatment of infec-
tion is prompt institution of effective empiric antibiotics, especially in patients with 
neutropenic fever. Optimization of empiric therapy requires a knowledge of likely 
antimicrobial resistance patterns, especially given that neutropenic patients can 





Control of emerging resistant organisms remains one 
of the major challenges for the future. One strategy to achieve 
this is prospectively monitoring bacterial susceptibility rates. 
The effect of such intervention strategies on the prevention and 
control of nosocomial infections has been documented.4
In 1995, after years of using a third-generation cepha-
losporin (ceftazidime) in combination with a glycopeptide 
as empiric therapy for neutropenic fever, we were confronted 
with a high resistance rate of inducible Enterobacteriaceae 
to ceftazidime.5 Consequently, in May 1995, we introduced 
a new combination therapy comprising a fourth-generation 
cephalosporin (cefepime) and an aminoglycoside (amikacin) 
for the empiric treatment of fever in neutropenic patients in 
our hematology unit.
The aim of this prospective study was to analyze trends 
in the bacterial spectrum and antibiotic susceptibilities of 
bacterial isolates in relation to empiric treatment during a 
long-term (15-year) follow-up period in our unit.
Materials and methods
This prospective, open-label, epidemiologic study was 
  conducted between 01 January 1994 and 31 December 2008 
in the hematology ward at Antwerp University Hospital. 
This is a tertiary center including units for treatment of acute 
leukemia and hematopoietic stem cell transplantation. The 
patient population consisted of adults with acute and chronic 
leukemias (around 50%), lymphomas (around 25%), or other 
hematologic malignancies. About 25% of patients were 
hospitalized for transplantation.
Bacterial cultures
All hospitalized hematology patients with neutropenia were 
included in the study. Fever was defined as two   consecutive 
axillary temperature recordings of 38°C or higher in a 
12-hour period, or as a single recording of 38.5°C or higher. 
Patients were considered neutropenic if they had fewer than 
500 neutrophils/mm³ or if the absolute neutrophil count was 
greater than 500/mm³ and less than 1000/mm³, but decreasing 
progressively and expected to be less than 500/mm³ within 
24–48 hours. The standard protocol required “inventory” 
cultures to be taken once a week from all patients with 
neutropenia (with or without fever) and twice a week from 
hematopoietic stem cell transplantation patients. The cultures 
consisted of skin swabs (from nose, throat, ears, axilla, groin, 
perianal region, vagina, or preputium), a urine culture, and a 
stool culture. In cases of neutropenic fever, three sets (each 
set consisting of one aerobic and one anaerobic) of blood 
cultures were taken, as well as a midstream urine culture, and 
throat swabs before starting empiric antibiotics, according to 
the protocol. Suspected foci of infection were also cultured. 
In cases of persistent fever, one set of blood cultures was 
taken on each day.
All bacterial isolates were cultured and tested when 
appropriate for antibiotic susceptibility using Kirby-Bauer 
disk diffusion according to the standards of the Clinical and 
Laboratory Standards Institute (CLSI). Breakpoints were 
based on CLSI guidelines.6 Pathogens with intermediate 
susceptibility were considered resistant. In the analysis for 
susceptibility testing, each pathogen was calculated only 
once per patient and per type of isolate. The total number of 
hospitalizations per year for neutropenia was retrieved from 
hospital administration records. All data were collected using 
dBase IV till 1996, and 1997 Microsoft Access software 
thereafter. To avoid interference, no major changes in hygiene 
procedures were made.
Treatment
From February 1991 until the end of April 1995 (before the 
start of this study), patients were treated with ceftazidime 
2 g tid intravenously (IV) in combination with vancomycin 
1 g bid IV or teicoplanin 1200 mg/day IV, followed by 
800 mg/day IV . At the start of this study in May 1995, the 
empiric regimen was changed to cefepime 2 g tid IV and 
amikacin as a loading dose of 25 mg/kg (if renal function 
was normal)   followed by 15 mg/kg/day IV. Vancomycin 
or teicoplanin were added after 48 hours based on   clinical 
(eg, persistent fever) or microbiologic results. If fever 
persisted for at least an additional 48 hours, ceftazidime or 
cefepime were replaced by imipenem-cilastatin or   meropenem 
1 g tid IV . The oral antibiotic prophylaxis policy was stable, 
ie, fluoroquinolones (ciprofloxacin 500 mg bid or levofloxacin 
500 mg once daily) and/or   trimethoprim-sulfamethoxazole 
(160 mg + 800 mg bid), the latter being for stem cell transplant 
patients. Oral antibiotic prophylaxis was discontinued after 
initiation of the empiric antibiotic regimen. The total con-
sumption of antibiotics (in grams) was obtained from the phar-
macy   department and was converted to defined daily doses 
(DDDs) per 100 patient days for the years 1994–2008.
statistical analysis
Because repeated measures were taken for the bacteria, a 
correlation has to be taken into account when analyzing 
the data. We used linear mixed models to account for the 
heterogeneity across the bacteria (and homogeneity within 
the bacteria). Stepwise model selection was used to identify 
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Figure 1 Gram-classification of the isolated bacteria in all cultures (1994–2008).
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interaction effects. P , 0.05 was considered statistically 




During the 15 years of follow-up, a total of 3624 bacteria 
(Gram-positive and Gram-negative) were isolated and   cultured 
(Figures 1 and 4). Gram-positive bacteria were more common 
(n = 1928, 53.2%) than Gram-negative   bacteria (n = 1696, 
46.8%) throughout the study period. No   significant difference 
was observed between the   proportion of Gram-positive and 
Gram-negative isolates. A decrease in the total number of 
isolates was observed during the study period (P , 0.0001). 
This was not due to fewer   hospitalizations for neutropenia.
The most common Gram-positive isolates were coagulase-
negative Staphylococci resistant for oxacillin (n = 1153, 
31.8%). Of these bacteria, 994 samples were isolated 
from blood cultures. Other isolated   coagulase-negative 
  Staphylococci were oxacillin-sensitive (n = 534, 14.7%); 389 
bacteria were isolated from blood cultures.   During follow-up, 
a statistically significant shift to the more   oxacillin-resistant 
phenotypes occurred (confidence interval [CI] 32.6–49.88).
S. aureus was isolated in 262 (7.2%) cases. Only 48 isolates 
(1.3%) were methicillin-resistant (Figure 2). There was a sig-
nificant decrease in S. aureus isolates (P , 0.0001) throughout 
the study period. Among the Gram-negative bacteria, the 
majority were Escherichia coli (n = 910, 25%). A significant 
decrease in isolates was seen (P = 0.0006).   Enterobacteriaceae 
was isolated in 567 (15.6%) cases. Of these, 306 isolates were 
inducible Enterobacteriaceae (  Enterobacter spp, Serratia 
spp, Morganella morganii,  Citrobacter spp, Providencia spp, 
and Pantoea   agglomerans, 8.4%). A significant decrease over 
time of inducible   Enterobacteriaceae was noted (P = 0.0027). 
Pseudomonas aeruginosa was isolated in 140 (3.8%) cases 
(Figure 3).
Antibiotic susceptibility trends
The antibiotics tested and the percentages of isolates with 
decreased susceptibility are listed in Tables 1 and 2 (for 
Gram-positive and Gram-negative isolates, respectively). 
Data are provided for most frequently encountered bacte-
ria for all cultures. Antibiotic susceptibility data for blood 
cultures are provided separately for oxacillin-sensitive and 
oxacillin-resistant coagulase-negative Staphylococci.
No significant decrease in susceptibility was noted for 
  methicillin-sensitive S. aureus (MSSA). MSSA isolates 
remained susceptible to ciprofloxacin, cotrimoxazole, and 
amikacin. None of the 48 methicillin-resistant S. aureus 
(MRSA) isolates showed true vancomycin resistance (data 
not shown).
Among the oxacillin-sensitive, coagulase-negative 
  Staphylococci, 60%–70% were not susceptible to penicillin. 
Some lower susceptibility rates against cefepime were noted at 
the start of the follow-up period, but this disappeared with time. 
Vancomycin, teicoplanin, amikacin, meropenem, cefepime, and 
amoxycillin-clavulanic acid remained equally effective against 
oxacillin-sensitive, coagulase-negative Staphylococci.
The oxacillin-resistant coagulase-negative Staphylococci 
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Figure 2 Isolated Gram-positive bacteria in all cultures (1994–2008).
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Figure 3 Isolated Gram-negative bacteria in all cultures (1994–2008).





of the oxacillin-resistant, coagulase-negative   Staphylococci 
were susceptible to amikacin. A significant increase in sus-
ceptibility to cotrimoxazole was observed (P = 0.0073). No 
difference was observed between blood and other cultures 
for these bacteria.
E. coli had a low susceptibility rate to ampicillin of 
approximately 40%. Additionally, piperacillin showed a 
very low activity. A major problem existed for prophylactic 
antibiotics. A low susceptibility rate was noted for cipro-
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Table 1 Behavior of antimicrobial sensitivity of gram-positive bacteria isolated in the period 1994–2008
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
MSSA, all cultures
n 24 16 18 19 12 10 14 14 12 17 11 14 10 12 11
Penicillin 83.8 87.5 88.9 89.5 100 90.0 85.7 78.6 91.7 88.2 90.0 91.7 66.7 100 90.9
Oxacillin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Amikacin 0 0 5.6 5.3 0 0 0 0 0 0 0 0 0 0 0
cotrimoxazole 0 0 11.1 5.3 0 0 14.3 0 0 0 0 0 0 0 0
Ciprofloxacin – 12.5 33.3 15.8 0 0 0 0 8.3 0 – – 0 0 0
Vancomycin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Teicoplanin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
CNS, oxacillin-sensitive, all cultures
n 56 48 52 27 45 36 23 32 22 27 30 25 31 26 42
Penicillin 66.1 79.2 73.1 74.1 48.9 66.7 60.9 53.1 50.0 55.6 56.7 56 66.7 80.8 73.8
Amoxy-clav 0 2.1 7.7 0 2.2 2.8 4.3 0 0 – – – – – –
Oxacillin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Meropenem – – – – 2.2 0 4.3 0 0 – – – – – –
cefepime – 12.5 7.7 3.7 2.3 8.3 4.3 0 0 – – – – – –
Amikacin 0 0 3.8 0 2.2 0 4.3 0 0 0 0 0 3.2 0 0
cotrimoxazole 17.9 18.8 11.5 11.1 13.3 16.7 13.0 3.1 0 3.7 16.7 24.0 22.6 23.1 26.2
Ciprofloxacin – 29.2 15.4 11.1 15.6 11.1 17.4 3.1 27.3 16.7 – – 50.0 53.8 42.9
Vancomycin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Teicoplanin 0 2.1 0 0 0 0 0 0 0 0 0 0 3.2 0 0
CNS, oxacillin-sensitive, blood cultures
n 47 35 38 27 39 30 20 29 16 22 20 17 22 16 26
Penicillin 68.1 77.1 76.3 74.1 48.7 63.3 65.0 51.7 43.8 59.1 55.0 47.1 71.4 87.5 84.6
Amoxy-clav 0 2.9 5.3 0 2.6 3.3 5 0 0 – – – – – –
Oxacillin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Meropenem – – – – 2.6 0 0 0 0 – – – – – –
cefepime – 10.0 5.3 3.7 2.6 10.0 0 0 0 – – – – – –
Amikacin 0 0 5.3 0 2.6 0 0 0 0 0 0 0 4.5 0 –
cotrimoxazole 8.3 7.7 15.8 11.1 12.8 16.7 0 3.4 0 4.5 20.0 17.6 22.7 37.5 30.8
Ciprofloxacin – 15.4 21.1 11.1 15.4 13.3 0 3.4 0 20.0 0 – 50.0 68.8 50.0
Vancomycin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Teicoplanin 0 0 0 0 0 0 0 0 0 0 0 0 4.5 0 0
Levofloxacin
CNS, oxacillin-resistant, all cultures
n 93 80 84 105 65 58 49 84 56 66 75 82 103 73 80
Penicillin 100 97.4 100 99.0 100 100 100 96.4 100 100 98.7 96.9 98.6 94.7 98
Amoxy-clav 40.0 71.4 71.4 73.3 67.7 67.2 69.4 61.9 91.1 – – – – – –
Oxacillin 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Meropenem – – – – 50.8 63.8 63.3 60.7 28.6 – – – – – –
cefepime – 71.4 59.5 53.3 53.8 60.3 57.1 73.8 63.6 – – – – – –
Amikacin 6.7 28.8 29.8 24.8 29.2 27.6 46.9 28.6 32.1 27.3 29.7 23.2 24.5 17.8 –
cotrimoxazole 53.3 60.0 67.9 79.0 64.6 56.9 71.4 44.0 51.2 74.3 78.7 70.7 69.6 61.1 70.0
Ciprofloxacin – 77.5 70.2 85.7 80.0 75.9 87.7 65.5 83.9 72.7 0 – 75.0 85.7 89.8
Vancomycin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Teicoplanin 0 0 0 1.0 1.5 1.7 4.1 1.2 1.8 4.5 1.3 2.4 0 1.4 1.3
CNS, oxacillin-resistant, blood cultures
n 89 71 79 91 61 48 45 75 47 62 59 71 81 57 58
Penicillin 100 97.1 100 98.9 100 100 100 96.0 100 100 98.3 96.5 98.5 93.3 100
Amoxy-clav 30.8 76.5 72.2 73.6 67.2 64.6 75.6 64.0 89.4 – – – – – –
Oxacillin 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Meropenem – – – – 52.5 62.5 66.7 62.7 32 – – – – – –
cefepime – 77.8 60.8 52.7 52.5 58.3 62.2 72.0 61.9 – – – – – –
Amikacin 0 29.6 30.4 24.2 29.5 27.1 51.1 32.0 31.8 29.0 28.8 19.7 22.2 22.9 –
cotrimoxazole 46.2 57.7 68.4 81.3 62.3 62.5 75.6 44.0 51.0 74.2 76.3 70.4 67.9 69.6 60.3
Ciprofloxacin – 74.6 68.4 84.6 78.7 75.0 88.9 64.0 83.1 72.7 – - 66.7 88.9 90.0
Vancomycin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Teicoplanin 0 0 0 1.1 1.6 2.1 4.4 1.3 2.1 4.8 0 2.8 0 1.8 1.7
Levofloxacin – – – – – – – – – 78.3 83.7 82.7 76.7 – –
Notes: n, number of isolates; –, not tested; shown results indicate decreased sensitivity.





Table 2 Behavior of antimicrobial sensitivity of gram-negative bacteria isolated in the period 1994–2008
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
E. coli, all cultures
n 74 72 55 93 64 61 38 44 39 57 53 59 63 69 69
Ampicillin 60.8 59.7 52.7 72.0 53.1 63.9 55.3 65.9 61.5 33.3 58.5 62.1 63.5 60.3 70.1
Amoxy-clav 5.4 16.7 3.6 11.8 7.8 14.8 15.8 0 0 3.5 9.4 6.8 7.9 17.4 13.4
Piperacillin 40.5 40.3 41.8 61.3 37.5 45.9 36.8 56.8 46.2 63.8 53.9 – – – –
ceftazidime 5.4 4.2 0 4.3 0 13.1 5.3 0 2.6 5.3 3.8 1.7 0 3.2 14
cefepime 2.7 0 0 0 0 11.5 0 0 2.6 3.5 0 0 0 1.6 7.3
Meropenem – – – – 0 1.6 0 0 0 0 0 0 0 0 0
Imipenem 0 0 0 0 – – – – – – – – – – –
Amikacin 1.4 0 0 0 0 1.6 0 0 0 0 1.9 0 1.6 0 1.4
Ciprofloxacin 31.5 35.2 29.1 38.7 26.6 42.6 28.9 36.4 38.5 26.1 – 9.1 49.3 40.6
cotrimoxazole 44.6 40.3 49.1 53.8 40.6 57.4 39.5 47.7 48.7 35.1 34.0 51.7 52.4 56.5 50.7
Non-inducible Enterobacteriaceae, all cultures
n 16 15 25 27 28 22 11 12 7 11 24 13 19 19 13
Ampicillin 68.8 80 80 70.4 78.6 68.2 90.9 75 85.7 54.6 75.0 84.6 78.9 81.3 69.2
Amoxy-clav 12.5 26.7 16.0 7.4 3.6 9.1 0 8.3 14.3 0 16.7 30.8 5.3 26.3 16.7
Piperacillin 31.3 33.3 20.0 29.6 35.7 27.3 36.4 33.3 14.3 9.1 20.8 – – – –
ceftazidime 25.0 6.7 12.0 9.0 17.9 9.1 9.1 0 0 0 0 7.7 0 0 0
cefepime 6.7 9.1 0 0 3.6 4.5 0 8.3 0 0 0 7.7 0 0 0
Meropenem – – – – 0 0 0 0 0 0 0 0 5.3 5.3 0
Imipenem 0 6.7 0 0 – – – – – – – – – – –
Amikacin 0 6.7 0 0 0 4.5 0 0 0 0 0 7.7 5.3 5.3 0
Ciprofloxacin 12.5 0 0 38.7 10.7 4.5 36.4 25.0 14.3 0 – – 0 10.5 7.7
cotrimoxazole 12.5 6.7 12.0 30.0 28.6 13.6 45.5 33.3 14.3 9.1 16.7 7.7 15.8 15.8 23.1
Inducible Enterobacteriaceae, all cultures
n 36 37 26 20 26 15 12 18 10 16 16 17 22 16 19
Ampicillin 94.4 80.6 84.6 85.0 72.7 73.3 83.3 88.9 80.0 100 81.3 94.1 95.5 93.8 78.9
Amoxy-clav 88.9 75.0 84.6 85.0 72.7 86.7 66.7 77.8 80.0 68.8 62.5 88.2 81.8 87.5 57.9
Piperacillin 72.2 48.6 30.8 15.0 36.4 13.3 16.7 22.2 10.0 75.1 37.5 – – – –
ceftazidime 75.0 35.1 30.8 15.0 31.8 13.3 8.3 11.1 10.0 62.8 37.5 47.1 36.4 37.5 35.5
cefepime 13.9 0 7.7 0 0 0 0 0 0 12.5 0 17.6 4.5 12.5 12.5
Meropenem – – – – 4.6 0 0 0 0 0 0 5.9 0 0 0
Imipenem 0 0 0 5.0 – – – – – – – – – – –
Amikacin 36.1 18.9 0 5.0 18.2 6.7 0 0 0 18.8 6.3 11.8 13.6 0 15.8
Ciprofloxacin 52.8 24.3 15.4 10.0 31.8 6.7 33.3 5.6 10.0 60.0 - 33.3 25.0 33.3
cotrimoxazole 52.8 33.3 11.5 10.0 40.9 6.7 0 5.6 10.0 50.0 31.3 35.3 22.7 31.3 47.4
Pseudomonas aeruginosa, all cultures
n 15 7 13 14 11 8 3 10 6 8 10 5 14 7 9
Piperacillin 0 14.3 0 14.3 18.2 12.5 – 0 0 12.5 10.0 – – – –
ceftazidime 0 0 0 0 9.1 12.5 – 0 0 12.5 20.0 0 28.6 14.3 11.1
cefepime 53.3 25.0 0 14.3 9.1 12.5 – 0 0 25.0 10.0 20.0 21.4 14.3 11.1
Imipenem 0 14.3 15.4 21.4 – – – – – – – – – – –
Meropenem – – – – 18.2 0 – 0 0 25.0 10.0 20.0 7.1 14.3 33.3
Amikacin 0 0 0 7.1 0 0 – 0 0 25.0 10.0 0 7.1 0 11.1
Ciprofloxacin 6.7 16.7 0 7.1 18.2 0 – 0 0 0 – – 100 14.3 22.2
Notes: n, number of isolates; –, not tested; shown results indicate decreased sensitivity.
Susceptibility of E. coli to cefepime remained higher than 
to ceftazidime and amoxycillin-clavulanate. Up to 44% of 
the E. coli isolates in blood cultures showed susceptibility to 
ciprofloxacin (data not shown). The most active antibiotics 
against E. coli were meropenem and amikacin.
Cefepime, amikacin, and meropenem remained very active 
against noninducible Enterobacteriaceae. The   susceptibility 
rate to ceftazidime improved after stopping its use in the 
empiric antibiotic regimen, rising from 75% to 100%. There 
was a statistically significant increase in susceptibility for 
piperacillin (P = 0.0390), a statistically significant decrease 
in susceptibility to cefepime (P = 0.0298), and a borderline 
statistically significant decrease in susceptibility to cipro-
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Figure 4 Characteristics of the isolated bacteria (1994–2008).
Abbrevations:  cnA,  coagulase-negative  Staphylococci;  cns  oxa-R,  cns  oxacillin-resistant;  cns  oxa-s,  cns  oxacillin-sensitive;  MssA,  methicillin-sensitive  S.  aureus; 
MRsA, methicillin-resistant S. aureus.
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For inducible Enterobacteriaceae, cefepime remained as 
active as before (after several years of usage). Together with 
meropenem, cefepime remained the most active antibiotic in 
this category of bacteria. The susceptibility rate to ceftazidime 
improved from 30% to 65% (P = 0.0136), but remained lower 
than that of cefepime. Susceptibility rates to amikacin tended 
to improve, as did those to meropenem. The susceptibility 
of inducible Enterobacteriaceae for ciprofloxacin gradually 
deteriorated (66.7%). Furthermore, cotrimoxazole showed a 
low susceptibility to these bacteria (42.6%). However, they 
were still more efficient than ceftazidime.
P . aeruginosa had a low susceptibility rate to cefepime 
at the start of the follow-up period. Although this low sus-
ceptibility rate increased over time, it remained equal to the 
susceptibility rate of ceftazidime. A decreasing susceptibility 
rate to meropenem was also apparent.
Antibiotic usage
The analysis of antibiotic consumption according to DDDs 
showed a stable consumption of amikacin, quinolones, 
and meropenem during the years of the study (Figure 5). 
There was a statistically significant increase in use of cefepime 
(P = 0.0001) and a significantly decrease in use of ceftazidime 
(P = 0.0393).
Discussion
After several years of using the new empiric antibiotic therapy, 
a continuing good profile of decreasing incidence of inducible 
Enterobacteriaceae was seen in our study. After the change 
in antibiotic policy, further increasing   susceptibility for 
  ceftazidime was observed. This is a long-term   confirmation 
of our own observations and those of others.5,7 Moreover, 
during the 15 years of follow-up, no significant decrease was 
seen in susceptibility of these bacteria against the empiric 
antibiotics used, particularly cefepime and amikacin. To our 
knowledge, this is the first report showing that long-term 
use of cefepime and amikacin has no significant effect on 
susceptibility rates of inducible Enterobacteriaceae in neu-
tropenic patients.
An international, well documented balance of predomi-
nantly occurring pathogens has existed since the 1980s. In 
this balance, Gram-positive organisms continue to be the 
more common organisms in most hospitals.8,9 In our survey, 
the relative proportion of Gram-negative and Gram-positive 
isolates remained stable. Consistent with other international 
studies, a slight preponderance of Gram-positive organisms 
was observed in our survey.
However, this is in contrast with data obtained in some 
other centers, where an increasing number of Gram-negative 
isolates has been observed in recent years, nearly equaling 
the Gram-positive isolates.10 This was confirmed in a recent 
French study in patients with febrile neutropenia.11 In this 
study, 51% of the documented microbiologic infections were 
Gram-negative between 2001 and 2003.11 The reason for this 
change is probably a result of complex interactions involving 























1994 1995 1996 1997 1998 1999 2000 20012002 2003 2004 2005 2006 2007 2008
Amikacin DDD 1 g Cefepime DDD 2 g
Meropenem DDD 2 g
Levofloxacin DDD 0,5 g
Ceftazidime DDD 4 g
Ciprofloxacin DDD 1 g
Figure 5 Antibiotic consumption in the hematology ward (1994–2008).
Abbrevation: DDD, defined daily doses.





antibiotic use, prolonged hospitalization, and the quality of 
care provided.12
Regarding the Gram-positive isolates in our survey, the most 
common ones were the coagulase-negative Staphylococci, with 
a significant shift from oxacillin-sensitive to oxacillin-resistant 
organisms over the years, which occurred in blood cultures as 
well. In recent years, coagulase-negative Staphylococci has been 
recognized as one of the leading causes of bacteremia in patients 
suffering from neutropenia.12–14 A possible explanation for this 
observation could be the regional use of prophylactic quinolones. 
The prevalence of MRSA differs markedly among the   European 
countries (from ,1% to 80%), with the lowest rate in the Scan-
dinavian countries.14 In our study, only 1.3% of S. aureus isolates 
were methicillin-resistant, which can be   considered favorable. 
The exact reason for this is unclear.   Possible explanations could 
be the strict infection control   measures applied to infected 
patients, frequent screening cultures, and rigorous hand hygiene 
procedures. None of the Gram-positive bacterial isolates in our 
survey was vancomycin-resistant, probably reflecting a low 
consumption of glycopeptides.
Several reports of reduced ciprofloxacin   susceptibility 
in E. coli and other Gram-negative bacteria have been pub-
lished.7,14,15 This is confirmed by our results, which show a 
consistently reduced susceptibility of Gram-negative   bacteria 
to ciprofloxacin. This was noted for E. coli, inducible Enter-
obacteriaceae, and P. aeruginosa (approximately 40%, 30%, 
and 20% reduced susceptibility, respectively). In our survey, 
only 34% of isolates in blood cultures were susceptible to 
ciprofloxacin, which is of major concern. One of the possible 
explanations for this is the prior use of quinolones, which 
have been identified as a risk factor for infection with resistant 
Gram-negative bacteria.15
P . aeruginosa was present only in 3.8% of our isolates, 
which is in accordance with other studies.7,9,13 The suscep-
tibility to the broad-spectrum antibiotics (ceftazidime and 
cefepime) remained stable during the observation period. 
However, reduced susceptibility of P . aeruginosa to ceftazi-
dime, cefepime, and meropenem of 11%–33% is a cause for 
concern. This susceptibility pattern highlights the necessity 
for continuous surveillance, and can be a reason to start 
empiric treatment for neutropenic fever with combination 
therapy targeting Gram-negative infections.16
Our study has some limitations. In particular, it only 
gives information about local susceptibility patterns. A future 
investigation could include combined analysis of blood, 
clinical, and surveillance cultures. However, given that only 
15%–25% of patients with neutropenia develop bloodstream 
infections, we argue that clinicians should consider the entire Infection and Drug Resistance
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spectrum of bacterial infections when deciding about empiric 
antibiotic therapy.
Conclusion
A good susceptibility pattern of inducible Enterobacteri-
aceae was maintained over 15 years following the intro-
duction of amikacin and cefepime. Although the number 
of Gram-negative bacteria was rising, the Gram-positive 
bacteria remained the main pathogens. Coagulase-negative 
Staphylococci were the most frequently isolated pathogens, 
with an increase in oxacillin-resistance. No true vancomycin 
resistance was noted. Another finding was the low suscepti-
bility of ciprofloxacin against E. coli, inducible Enterobac-
teriaceae, and P . aeruginosa. The decreased susceptibility 
of P . aeruginosa to most antibiotics is a major concern. 
Continuous monitoring of susceptibility rates is thus war-
ranted, whereby careful selection of antibiotics could reduce 
bacterial resistance.
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